Clinical Trials

Phase 1/2 Active not recruiting

Breast Neoplasms

NCT03157128 2026-04-16

LIBRETTO-001

857 enrolled 24 charts 6 FDA

BreastCNSEndocrineGastrointestinalHead & NeckThoracic

Thyroid Cancer, Papillary, Breast Neoplasms, Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Head and Neck Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms, Thyroid Diseases, Thyroid Neoplasms, Central Nervous System Neoplasms, Carcinoma, Medullary

NCT04421963 2026-04-16

ROSY-O

Phase 3 Active not recruiting

185 enrolled

Phase 3 Active not recruiting

Breast Neoplasms, Neoplasms, Ovarian Neoplasms

NCT05296798 2026-04-16

A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)

922 enrolled

Breast Neoplasms

NCT07060807 2026-04-16

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

1,000 enrolled

Breast Neoplasms

NCT07062965 2026-04-16

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

400 enrolled

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

NCT07085767 2026-04-16

OPERA-02

1,000 enrolled

Breast Neoplasms

NCT07229313 2026-04-16

A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors

BreastGastrointestinalGynecologicHead & NeckSarcomaThoracic

76 enrolled

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04072952 2026-04-15

mBC

Phase 1/2 Completed

217 enrolled

Breast Neoplasms

NCT05877599 2026-04-15

A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

BreastGastrointestinalGynecologicHead & NeckThoracic

45 enrolled

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Colorectal Neoplasms

NCT06120283 2026-04-15

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

Phase 2 Active not recruiting

399 enrolled

BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT06324357 2026-04-15

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Phase 1/2 Recruiting

768 enrolled

BreastGastrointestinal

Adenocarcinoma Of Esophagus, Breast Neoplasms, Colorectal Neoplasms

NCT06840483 2026-04-15

Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer

66 enrolled

Breast Neoplasms

NCT07222267 2026-04-15

An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors

86 enrolled

Breast Neoplasms

NCT07243002 2026-04-15

REPOWER

Recruiting

3,000 enrolled

Breast Neoplasms

NCT04085653 2026-04-14

Managed Access Programs for BYL719, Alpelisib

Available

Breast Neoplasms

NCT05238922 2026-04-14

Study of INCB123667 in Subjects With Advanced Solid Tumors

BreastGastrointestinalGynecologic

604 enrolled

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Digestive System Neoplasms

NCT05377996 2026-04-14

A Study of XMT-1660 in Participants With Solid Tumors

319 enrolled

Breast Neoplasms, Carcinoma, Adenoid Cystic, Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05827081 2026-04-14

Adjuvant WIDER

1,400 enrolled

Breast Neoplasms, Breast Neoplasms, Male

NCT07311993 2026-04-14

Phase 1 Study of CLR 125 in Triple Negative Breast Cancer

60 enrolled

Phase 1/2 Not yet recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02802423 2026-04-13

Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer.

44 enrolled

Phase 2 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04225117 2026-04-13

A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

329 enrolled 23 charts

BreastGastrointestinalHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Triple Negative Breast Neoplasms

NCT04553133 2026-04-13

PF-07104091 as a Single Agent and in Combination Therapy

Phase 2 Active not recruiting

157 enrolled

BreastGynecologicThoracic

Breast Neoplasms, Ovarian Neoplasms, Small Cell Lung Carcinoma

NCT04767594 2026-04-13

PERFORM

Active not recruiting

1,407 enrolled

Breast Neoplasms

NCT05038631 2026-04-13

Managed Access Programs for LEE011, Ribociclib

Available

Breast Neoplasms

NCT05180474 2026-04-13

GEN1047 for Solid Tumors - First in Human (FIH) Trial

Phase 1/2 Terminated

179 enrolled

BreastDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmSarcomaThoracic

Breast Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT05461430 2026-04-13

TraveraRTGx

Completed

72 enrolled

Anus Neoplasms, Appendiceal Neoplasms, Ascites, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Laryngeal Neoplasms, Lung Neoplasms, Melanoma, Mesothelioma, Mouth Neoplasms, Nasopharyngeal Neoplasms, Neoplasms, Unknown Primary, Oropharyngeal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Penile Neoplasms, Stomach Neoplasms, Thymoma, Vulvar Neoplasms, Pleural Effusion, Malignant, Carcinoma, Neuroendocrine, Cholangiocarcinoma, Carcinoma, Small Cell, Carcinoma, Pancreatic Ductal, Gastrointestinal Stromal Tumors

NCT05509790 2026-04-13

A Study of LY3484356 in Chinese Participants With Advanced Breast Cancer

Phase 1 Active not recruiting

17 enrolled

Breast Neoplasms

NCT05774951 2026-04-13

CAMBRIA-1

4,300 enrolled

Breast Neoplasms

NCT06253871 2026-04-13

A Phase 1/1b Study of IAM1363 in HER2 Cancers

BreastCNSGastrointestinalThoracic

383 enrolled

Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasms, Stomach Neoplasms

NCT06582017 2026-04-13

Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

BreastGastrointestinalGenitourinaryGynecologicThoracic

100 enrolled

Breast Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Gastrointestinal Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT06625775 2026-04-13

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

BreastGastrointestinalThoracic

392 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis, Colorectal Neoplasms

NCT06746688 2026-04-13

A First-in-human, Clinical Trial Assessing the Safety of ES2B-C001-S01 With or Without [Adjuvant] in Patients With HER2-expressing Metastatic Breast Cancer.

40 enrolled

Breast Neoplasms

NCT06810804 2026-04-13

A Phase IIa Study to Evaluate NBQ72S

Phase 2 Recruiting

10 enrolled

Breast Neoplasms

NCT07007559 2026-04-13

ASPEN-09-03

Phase 2 Recruiting

120 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT07368998 2026-04-13

optINAVO

Phase 2 Recruiting

80 enrolled

Breast Neoplasms

NCT07408089 2026-04-13

KOMODO-1

96 enrolled

Breast Neoplasms

NCT07512063 2026-04-13

A Study of Real-World Treatment Patterns and Outcomes Among HR+/HER2- Metastatic Breast Cancer Patients Treated With First-Line CDK4/6 Inhibitors

Completed

480 enrolled

Phase 1 Not yet recruiting

Breast Neoplasms

NCT07524322 2026-04-13

Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors

63 enrolled